Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELCNYSE:HHLANYSE:NVTANASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$12.15+6.1%$11.16$7.58▼$19.77$433.57M0.37282,671 shs224,653 shsHHLAHH&L Acquisition$10.75-0.3%$10.76$10.20▼$11.30$156.52M-0.01121,140 shs3,300 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsSERASera Prognostics$2.03+8.6%$2.26$1.37▼$9.13$70.45M0.72152,941 shs249,637 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+6.11%+3.14%+16.38%+16.38%-27.07%HHLAHH&L Acquisition0.00%0.00%0.00%0.00%0.00%NVTAInvitae0.00%0.00%0.00%0.00%-90.00%SERASera Prognostics+8.56%+10.33%+16.00%-48.35%-68.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCELCCelcuity1.1743 of 5 stars3.60.00.00.00.02.50.0HHLAHH&L AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.4686 of 5 stars0.02.00.00.01.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.17Buy$30.80153.50% UpsideHHLAHH&L Acquisition 0.00N/AN/AN/ANVTAInvitae 0.00N/AN/AN/ASERASera Prognostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HHLA, CELC, NVTA, and SERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.005/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/11/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.004/1/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$3.11 per shareN/AHHLAHH&L AcquisitionN/AN/A$1.71 per share6.29($1.19) per shareN/ANVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00SERASera Prognostics$115K665.01N/AN/A$1.40 per share1.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$111.78M-$3.03N/AN/AN/AN/A-96.21%-49.44%8/13/2025 (Estimated)HHLAHH&L Acquisition$17.69M-$0.14N/A∞N/AN/A-57.47%-0.35%N/ANVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ASERASera Prognostics-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)Latest HHLA, CELC, NVTA, and SERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CELCCelcuity-$0.95-$0.86+$0.09-$0.86N/AN/A5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million3/31/2025Q4 2024CELCCelcuity-$0.72-$0.85-$0.13-$0.85N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AHHLAHH&L AcquisitionN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity1.146.616.61HHLAHH&L AcquisitionN/A0.030.03NVTAInvitaeN/A2.392.25SERASera PrognosticsN/A2.022.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%HHLAHH&L Acquisition39.24%NVTAInvitae61.28%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipCELCCelcuity15.78%HHLAHH&L Acquisition0.54%NVTAInvitae0.74%SERASera Prognostics15.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4037.87 million31.89 millionOptionableHHLAHH&L AcquisitionN/A14.56 million14.48 millionNot OptionableNVTAInvitae1,700267.01 million284.37 millionOptionableSERASera Prognostics12037.67 million31.72 millionOptionableHHLA, CELC, NVTA, and SERA HeadlinesRecent News About These CompaniesSera Prognostics (NASDAQ:SERA) Raised to "Hold" at Wall Street ZenJune 22 at 1:45 AM | americanbankingnews.comSera Prognostics (NASDAQ:SERA) Rating Increased to Hold at Wall Street ZenJune 21, 2025 | marketbeat.comSera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $32,950.06 in StockJune 12, 2025 | insidertrades.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells 23,042 Shares of StockJune 11, 2025 | marketbeat.comWe Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth CarefullyJune 10, 2025 | finance.yahoo.comsera prognostics announces board elections and auditor ratificationJune 7, 2025 | investing.comSera Prognostics (NASDAQ:SERA) Rating Lowered to "Sell" at Wall Street ZenJune 7, 2025 | marketbeat.comAfter Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)May 29, 2025 | zacks.comSERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESMay 29, 2025 | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial ResultsMay 26, 2025 | finanznachrichten.deSERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCEMay 14, 2025 | prnewswire.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comDown -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a TurnaroundMay 13, 2025 | zacks.comSera Prognostics Inc (SERA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in StockMay 10, 2025 | insidertrades.comSera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial OfficerMay 9, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics reports Q1 2025 earnings beatMay 9, 2025 | investing.comSera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization ProgressesMay 9, 2025 | 360dx.comWhat I Wish I Knew: The Truth About Preterm Birth for Black WomenMay 9, 2025 | blackdoctor.orgSERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICERMay 8, 2025 | prnewswire.comSera Prognostics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHHLA, CELC, NVTA, and SERA Company DescriptionsCelcuity NASDAQ:CELC$12.15 +0.70 (+6.11%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$11.89 -0.26 (-2.17%) As of 04:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.HH&L Acquisition NYSE:HHLAHH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Sera Prognostics NASDAQ:SERA$2.03 +0.16 (+8.56%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$2.04 +0.01 (+0.49%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Why Qualcomm’s Latest Price Target Can't Be Ignored Texas Instruments Stock: Congress Likes It, Should You Too? Geospace Stock Skyrockets After Major Petrobras Contract Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs CrowdStrike Eyes Breakout as Cyber Threats Boost Demand Reddit Stock Ignites: Surge in Call Options Signals Big Bet Microsoft Stock Holds Steady as AI Drives Workforce Shift Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
